These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21819751)

  • 1. Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.
    Smith PK; Collins J
    Am J Rhinol Allergy; 2011; 25(4):e149-52. PubMed ID: 21819751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
    Meltzer EO; Hampel FC; Ratner PH; Bernstein DI; Larsen LV; Berger WE; Finn AF; Marple BF; Roland PS; Wall GM; Brubaker MJ; Dimas C; Potts SL; Silver LH; Barnes JR
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
    Lieberman P; Meltzer EO; LaForce CF; Darter AL; Tort MJ
    Allergy Asthma Proc; 2011; 32(2):151-8. PubMed ID: 21352639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis.
    Banov CH; Lieberman P;
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):28-35. PubMed ID: 11206234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.
    Ratner PH; Hampel FC; Amar NJ; van Bavel JH; Mohar D; Marple BF; Roland PS; Wall GM; Brubaker MJ; Drake M; Turner D; Silver LH
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):474-9. PubMed ID: 16312171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
    Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
    Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local treatment of aspecific nasal hyperreactivity with capsaicin.
    Filiaci F; Zambetti G; Ciofalo A; Luce M; Masieri S; Lovecchio A
    Allergol Immunopathol (Madr); 1994; 22(6):264-8. PubMed ID: 7892815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of the onset and duration of action of olopatadine nasal spray.
    Patel P; Roland PS; Marple BF; Benninger PJ; Margalias H; Brubaker M; Beezley SF; Drake M; Potts SL; Wall GM
    Otolaryngol Head Neck Surg; 2007 Dec; 137(6):918-24. PubMed ID: 18036421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis.
    Ozcan C; Vayisoglu Y; Doğu O; Görür K
    Am J Otolaryngol; 2006; 27(5):314-8. PubMed ID: 16935174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine releasability after adenosine challenge in subjects with allergic and non-allergic rhinitis: possible implications for mast cell priming.
    Polosa R; Pagano C; Low JL; Church MK; Crimi N
    Ann Ital Med Int; 1999; 14(2):86-93. PubMed ID: 10399370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carbachol nasal provocation test in vasomotor and polyposis rhinopathy].
    Latorre F; Fiorella R; Cassano P; Di Nicola V
    Acta Otorhinolaryngol Ital; 1989; 9(2):119-29. PubMed ID: 2763839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of nasal patency in patients with vasomotor rhinitis].
    Yang Y; Liu ZY; Zhang Y; Liu CY; Zhang L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Dec; 45(12):988-92. PubMed ID: 21215046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis.
    Corren J; Storms W; Bernstein J; Berger W; Nayak A; Sacks H;
    Clin Ther; 2005 May; 27(5):543-53. PubMed ID: 15978303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.
    Finegold I; Granet DB; D'Arienzo PA; Epstein AB
    Clin Ther; 2006 Oct; 28(10):1630-8. PubMed ID: 17157118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal ipratropium in the treatment of vasomotor rhinitis.
    Jokinen K; Sipilä P
    Rhinology; 1983 Dec; 21(4):341-5. PubMed ID: 6229864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
    Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nasal provocation test with hyperosmolar solutions: normal values].
    Cassano P; Latorre F
    Boll Soc Ital Biol Sper; 1991 Mar; 67(3):311-8. PubMed ID: 1930907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aspecific rhinoreactivity in the diagnosis of vasomotor rhinopathy: rhinomanometric study].
    Gregorio A; Castellano F
    Acta Otorhinolaryngol Ital; 1989; 9(5):497-502. PubMed ID: 2626954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intradermal tests using vasomotor agents in allergic rhinitis].
    Milosević DN; Janosević LjB; Janosević SB
    Srp Arh Celok Lek; 2000; 128(11-12):357-62. PubMed ID: 11337913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis.
    Lieberman P; Kaliner MA; Wheeler WJ
    Curr Med Res Opin; 2005 Apr; 21(4):611-8. PubMed ID: 15899111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.